US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% META $721.31 ▼-2.38%
FinancialContent

Articles published by Imunon, Inc.

News headline image
IMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
From Imunon, Inc.
Via GlobeNewswire
Tickers IMNN
News headline image
IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages
From Imunon, Inc.
Via GlobeNewswire
Tickers IMNN
News headline image
IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – December 1, 2022
From Imunon, Inc.
Via GlobeNewswire
Tickers IMNN
News headline image
IMUNON Announces Strategic Investment in Transomic Technologies
From Imunon, Inc.
Via GlobeNewswire
Tickers IMNN
News headline image
IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update
From Imunon, Inc.
Via GlobeNewswire
Tickers IMNN
News headline image
IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System
From Imunon, Inc.
Via GlobeNewswire
Tickers IMNN
News headline image
Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022
From Imunon, Inc.
Via GlobeNewswire
Tickers IMNN
News headline image
Imunon Appoints James E. Dentzer to its Board of Directors
From Imunon, Inc.
Via GlobeNewswire
Tickers IMNN
News headline image
Imunon Reports Partial Results from Ongoing Non-human Primate Study
From Imunon, Inc.
Via GlobeNewswire
Tickers IMNN
News headline image
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
From Imunon, Inc.
Via GlobeNewswire
Tickers IMNN